Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Pharmacokinetic candidates: CYP1A2
3. CYP2D6: variation in drug metabolism
4. CYP2D6 gene: hypothesis of TD
5. Why CYP1A2? (1)
6. CYP1A2 vs. CYP2D6: multi-dose vs. single-dose
7. Why CYP1A2? (2)
8. Functional polymorphism in CYP1A2
9. CYP1A2 Bsp I polymorphism: mean AIMS scores
10. Stratified analysis
11. TD and CYP1A2 gene: references
12. TD and other CYP genes: references
13. TD and CYP2D6 gene: meta-analysis
14. Other candidate genes: DRD2, DRD4, CYP2D6
15. Oxidative stress candidates: MnSOD gene
16. Free radical: hypotheses of TD
17. Free radicals, glutamatergic system and TD
18. MnSOD gene: hypothesis of TD
19. Why MnSOD?
20. Functional polymorphism in MnSOD
21. MnSOD A9V polymorphism: mean AIMS scores
22. TD and MnSOD gene: references
23. Gene-gene interactions
24. Models for specific gene-gene interactions (1)
25. Models for specific gene-gene interactions (2)
26. DRD3 Msc I polymorphism: mean AIMS scores
27. CYP1A2 Bsp I polymorphism: mean AIMS scores
28. DRD3 and CYP1A2 interactions
29. DRD3 and MnSOD interactions
30. DRD3 and BDNF interactions
31. DRD3 and 17-alpha-hydroxylase interactions
32. DRD3 and HTR2C interactions
33. Summary
34. Genetic association strategy: limitations
35. Possibilities for the future
36. Recommendations for future studies
37. Full models of prediction, artificial neural networks
38. How do we find these genes?
39. Contact information

Topics Covered

• Pharmacokinetics and TD: a look at the cytochrome P450 system
• Oxidative stress and TD: a look at free radicals and the superoxide dismutase genes
• Psychiatric pharmacogenetics as cleaner complex phenotypes
• Neuroimaging in pharmacogenetics: towards even cleaner phenotypes
• Complex traits and new statistical models for looking at multigene interactions with continuous variables
• Recommendations for future studies: bringing pharmacogenetics from "Bench to Bedside" and from "Bedside back to Bench"
• Onward towards individualized pharmacotherapy

Links

Series:

• Psychopharmacogenetics

Categories:

• Genetics & Epigenetics
• Neuroscience
• Pharmaceutical Sciences

Therapeutic Areas:

• Neurology

Talk Citation

Basile, V. (2007, October 1). Pharmacogenetics of tardive dyskinesia: a "movement" towards individualized therapy 2 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/MUTX3588.
Export Citation (RIS)

Publication History

• Published on October 1, 2007
• Archived on February 25, 2021

Financial Disclosures

• Dr. Vincenzo Basile has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.